Partial lipodystrophy
MONDO:0027767Loss and redistribution of subcutaneous and/or visceral adipose tissue from specific regions of the body.
21 clinical trials for this condition and its sub-types, 7 tagged with Partial lipodystrophy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Partial lipodystrophy
-
Familial partial lipodystrophy 13 trials · 14 incl. sub-types
10 sub-types
- Familial partial lipodystrophy, Dunnigan type 4 trials
- AKT2-related familial partial lipodystrophy 0 trials
- CIDEC-related familial partial lipodystrophy 0 trials
- LIPE-related familial partial lipodystrophy 0 trials
- PLIN1-related familial partial lipodystrophy 0 trials
- PPARG-related familial partial lipodystrophy 0 trials
- Autosomal semi-dominant severe lipodystrophic laminopathy 0 trials
- Familial partial lipodystrophy, Kobberling type 0 trials
- Lipodystrophy, familial partial, type 8 0 trials
- Lipodystrophy, familial partial, type 9 0 trials
-
Acquired partial lipodystrophy 6 trials
-
Hope for rare fat disorder: drug keeps working in Long-Term study
Disease control OngoingThis study gives the drug metreleptin to 29 people with partial lipodystrophy, a rare condition that causes high blood fats and diabetes. Participants have already shown improvement from the drug in earlier studies. The goal is to keep providing the treatment and check its long-t…
Phase 2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for rare fat disorder: daily leptin shots target blood sugar and fats
Disease control OngoingThis Phase 3 trial tests whether a daily injection of metreleptin (a lab-made leptin hormone) can improve blood sugar and fat levels in people with partial lipodystrophy, a rare condition where fat is distributed abnormally. About 69 participants will receive either metreleptin o…
Phase 3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a diabetes drug shrink dangerous belly fat in HIV patients?
Disease control OngoingThis study tests whether semaglutide, a drug used for diabetes, can reduce harmful belly fat and improve heart health in people with HIV who have excess fat around the midsection (lipohypertrophy). About 108 participants will receive either semaglutide or a placebo for 32 weeks. …
Phase 2 • Sponsor: Case Western Reserve University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC